Reports
Subscribe to
our newsletters!
Showing 49–60 of 65 results
-
July of 2022The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
-
June of 2022The report evaluates opportunities for ROR1-targeted drug modalities within the competitive landscape€ 1050.00
-
May of 2022This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00
-
May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
-
March of 2022This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2021€ 100.00
-
March of 2022This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022€ 2450.00
-
October of 2021Landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technologies from an industry perspective as of October 2021€ 2250.00
-
July of 2021This report provides you with a landscape description and analysis of direct in vivo delivery of nucleic acid-encoded antibodies employing DNA and mRNA platform technologies from an industry perspective as...€ 2150.00
-
March of 2021Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies, of selected biosimilars and other novel biologics in the calendar year 2020€ 100.00
-
May of 2020Report with a landscape analysis of Targeted Protein Degradation (TPD) technologies and of discovery and development of TPD drug candidates from an industry perspective as of May 2020€ 2050.00
-
March of 2020Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies and of selected biosimilars in the calendar year 2019€ 90.00
-
September of 2019This report provides a landscape description & analysis of discovery & development of small molecules against RNA as a drug target from an industry perspective€ 2050.00